EMEA-002551-PIP01-18 - paediatric investigation plan
capivasertib
PIPHuman
AstraZeneca AB (UK)
Tel.: +44 7384522139
E-mail: lee.anderson2@astrazeneca.com
P/0214/2019: EMA decision of 12 June 2019 on the granting of a product specific waiver for capivasertib (EMEA-002551-PIP01-18)